Apr 01, 2019
CLS Therapeutics Announces Presentation on “Frontiers in Cancer Immunotherapy” At The New York Academy Of Sciences

NEW YORK, April 1, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class Anc80-AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Frontiers in Cancer Immunotherapy” being held on May 14-15, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed Anc80) encoding DNase I of the treatment of pancreatic cancer animal model.

Mar 28, 2019

NEW YORK, March 28, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class Anc80-AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Targeting Tumor Heterogeneity” being held on May 8, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed Anc80) encoding DNase I of the treatment of pancreatic cancer animal model.

Aug 06, 2019

CLS Therapeutics Inc., an oncology focused gene therapy company, today announced that their project was selected as one of the 15 finalists to compete for the Boehringer Ingelheim Innovation Prize during the evening of August 15 at NYU Langone Health.

May 20, 2019

CLS Therapeutics Inc., a preclinical-stage biopharmaceutical company developing next-generation gene therapy anticancer drugs, today announced that George Tetz, MD, Ph.D., Chief Executive Officer, presented the poster, “CELL-FREE TUMOR DNA AND NEUTROPHIL EXTRACELLULAR TRAPS AS NOVEL THERAPEUTIC TARGETS FOR PANCREATIC CANCER” at the Frontiers in Cancer Immunotherapy organized by the New York Academy of Sciences May 14-15, 2019, in New York, New York.